Apotex Challenge To Abilify IP Won't Get High Court Hearing
The U.S. Supreme Court decided Monday not to review the Federal Circuit's so-called lead compound test for evaluating the obviousness of drug patents, denying an Apotex Inc. petition that argued the...To view the full article, register now.
Already a subscriber? Click here to view full article